{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:01:56Z","timestamp":1785182516215,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:00:00Z","timestamp":1528934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:00:00Z","timestamp":1528934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,7,3]]},"DOI":"10.1038\/s41416-018-0122-x","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T17:40:57Z","timestamp":1528825257000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["TGF\u03b2 shuts the door on T cells"],"prefix":"10.1038","volume":"119","author":[{"given":"Tobias","family":"Bald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,14]]},"reference":[{"key":"122_CR1","first-page":"215","volume":"134","author":"J Massague","year":"2008","unstructured":"Massague, J. TGFbeta in cancer.\u00a0Cell. 134, 215\u2013230 (2008).","journal-title":"Cancer Cell."},{"key":"122_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature02006","volume":"425","author":"R Derynck","year":"2003","unstructured":"Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577\u2013584 (2003).","journal-title":"Nature"},{"key":"122_CR3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nri2808","volume":"10","author":"RA Flavell","year":"2010","unstructured":"Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. & Licona-Limon, P. The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 10, 554\u2013567 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"122_CR4","first-page":"385","volume":"12","author":"RL Lin","year":"2015","unstructured":"Lin, R. L. & Zhao, L. J. Mechanistic basis and clinical relevance of the role of transforming growth factor-beta in cancer. Cancer Biol. Med. 12, 385\u2013393 (2015).","journal-title":"Cancer Biol. Med."},{"key":"122_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/ng.3225","volume":"47","author":"A Calon","year":"2015","unstructured":"Calon, A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47, 320\u2013329 (2015).","journal-title":"Nat. Genet."},{"key":"122_CR6","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello, D. V. F. et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538\u2013543 (2018).","journal-title":"Nature"},{"key":"122_CR7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"122_CR8","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde, P. S., Karanikas, V. & Evers, S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res. 22, 1865\u20131874 (2016).","journal-title":"Clin. Cancer Res."},{"key":"122_CR9","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MW Teng","year":"2015","unstructured":"Teng, M. W., Ngiow, S. F., Ribas, A. & Smyth, M. J. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 75, 2139\u20132145 (2015).","journal-title":"Cancer Res."},{"key":"122_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"122_CR11","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960\u20131964 (2006).","journal-title":"Science"},{"key":"122_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74\u201380 (2015).","journal-title":"Science"},{"key":"122_CR13","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"122_CR14","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-17-0189","volume":"23","author":"TA Aguilera","year":"2017","unstructured":"Aguilera, T. A. & Giaccia, A. J. Molecular pathways: oncologic pathways and their role in T-cell exclusion and immune evasion-a new role for the AXL receptor tyrosine kinase. Clin. Cancer Res. 23, 2928\u20132933 (2017).","journal-title":"Clin. Cancer Res."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0122-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0122-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0122-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T18:04:03Z","timestamp":1655316243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0122-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,14]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7,3]]}},"alternative-id":["122"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0122-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,14]]},"assertion":[{"value":"23 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.J. Smyth has research agreements with Bristol Myers Squibb, Tizona Therapeutics, and Aduro Biotech. The other author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}